Early in 2020, shocked citizens and social scientists predicted the widespread imposition of extreme “non-pharmaceutical interventions” in response to COVID would prove to have horrible and costly human and economic trade-offs — turns out they were right.
Philip Morris International has raised its bid against Carlyle to acquire Vectura, a U.K.-based drug manufacturer specializing in inhaled medicines, to 1.02 billion pounds ($1.41 billion). The U.K.'s Takeover Panel said that the deal could enter a rare head-to-head auction.
